🔗 Share this article

As America proceeds with historic adjustments to its immunization guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots in the pandemic and has zeroed in on potential deaths following Covid immunization in her brief position at the FDA.

Planned Overhauls to Childhood Immunization Program

Public health authorities had intended to reveal sweeping revisions to the pediatric vaccine schedule in December, aligning the US with the Danish vaccine program, according to reports – a significant shift that would put the US at odds with many the global community with no evidence for public health gain. This reveal has been postponed until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

Consolidating Power at the FDA

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the FDA – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more in line with Denmark's approach, a nation with universal health coverage and a population about the population of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – typically the responsibility of Prasad, head of the FDA’s CBER – rather than drug regulation.

Doubts Over Expertise

Høeg has no apparent track record in pharmaceutical research, oversight or administrative roles, which has been customary for former leaders of the CBER. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a large organization. She has no expertise in drug approvals.”

Former directors of the center would “understand regulatory frameworks and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who ran CBER have had.”

The drug center has an enormous workload at the agency, the former commissioner stated.

“The public just zeroes in on the novel medication approvals, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those have to be supervised,” Dr. Woodcock explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial management component to the position, which oversees over 5,000 employees. “It is a massive leadership role, if you execute it properly,” Woodcock added.

Official Statement and Controversial Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this selection indicates more teamwork among FDA leaders on immunizations, a spokesperson responded that the “inquiries are based on inaccurate assumptions”.

“Her experience matches the functions of her role,” the representative explained, citing the period Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s controversial expedited review system, a disputed rapid drug-approval program that allegedly concerned her predecessors. “By what process are these drugs being chosen for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he said, “the FDA seems to be moving towards less stringent oversight of most medications, aside from vaccines.”

Established History on Vaccines

Concerning immunizations, Høeg has a more documented, if concerning, history, critics observe. She authored a study using non-validated public submissions to estimate the rate of myocarditis following COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the current federal leadership included revising guidelines for new vaccines and halting “unnecessary” immunizations, she stated post-election on a audio program. At the FDA, Høeg has according to sources proposed barring adolescent males from getting COVID-19 vaccinations.

“She’s an all-around dogmatist who begins with her beliefs and tailors the evidence to fit the evidence in a very disingenuous, fraudulent fashion,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|